Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Receivables (2022 - 2025)

Amylyx Pharmaceuticals has reported Receivables over the past 4 years, most recently at $188000.0 for Q4 2025.

  • Quarterly results put Receivables at $188000.0 for Q4 2025, down 65.63% from a year ago — trailing twelve months through Dec 2025 was $188000.0 (down 65.63% YoY), and the annual figure for FY2025 was $188000.0, down 65.63%.
  • Receivables for Q4 2025 was $188000.0 at Amylyx Pharmaceuticals, down from $232000.0 in the prior quarter.
  • Over the last five years, Receivables for AMLX hit a ceiling of $40.6 million in Q4 2023 and a floor of $137000.0 in Q3 2022.
  • Median Receivables over the past 4 years was $3.0 million (2024), compared with a mean of $11.9 million.
  • Biggest five-year swings in Receivables: soared 21398.54% in 2023 and later tumbled 98.65% in 2024.
  • Amylyx Pharmaceuticals' Receivables stood at $15.8 million in 2022, then skyrocketed by 156.55% to $40.6 million in 2023, then tumbled by 98.65% to $547000.0 in 2024, then tumbled by 65.63% to $188000.0 in 2025.
  • The last three reported values for Receivables were $188000.0 (Q4 2025), $232000.0 (Q3 2025), and $203000.0 (Q2 2025) per Business Quant data.